article thumbnail

Bavarian Nordic engages US contract manufacturer to increase smallpox/monkeypox vaccine capacity

BioPharma Reporter

Bavarian Nordic has entered into an agreement with Grand River Aseptic Manufacturing (GRAM), a US based contract manufacturer, for fill and finish of the Jynneos smallpox/monkeypox vaccine in the country.

article thumbnail

Distributed Control System Facilitates Expansion for New Drugs Produced by Contract Manufacturing Organization

Pharma Mirror

Combatting the pandemic has highlighted the importance of the partnership between biopharma organizations and the contract manufacturing organizations (CMOs) that must flexibly handle outsourced production, which can come suddenly and often must quickly be ramped up.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

mRNA: A New Era in Biopharmaceutical Contract Manufacturing Market

Roots Analysis

The success of COVID-19 vaccines paved the path for mRNA-based drug products. However, synthesis and manufacturing of mRNA is fraught with several challenges as the production of such biomolecules is complex, cost intensive, requires specialized expertise and dedicated equipment.

article thumbnail

Biologics Contract Manufacturing – Current Interest of the Pharmaceutical Industry

Roots Analysis

Although biopharmaceuticals offer significant profit margins and have demonstrated the potential to treat a myriad of disease indications, they are generally associated with high costs of development and complex manufacturing protocols. Advanced and complex technologies are required for manufacturing, as well as testing of biopharmaceuticals.

article thumbnail

Amid contract manufacturing wind-down, Moderna advances production efforts for cancer programs

Fierce Pharma

. | To get a pulse on Moderna following its “year of transition” in 2023, look no further than the company’s manufacturing operations. The Cambridge, Massachusetts-based biotech has incurred a COVID-related wind-down charge on one hand, while it spends millions of dollars to bolster cancer vaccines at the same time.

article thumbnail

Vaccine Contract Manufacturing Global Market Forecast to Record Compound Annual Growth of 9% Between 2021-2026 – ResearchAndMarkets.com

BioTech 365

Vaccine Contract Manufacturing Global Market Forecast to Record Compound Annual Growth of 9% Between 2021-2026 – ResearchAndMarkets.com Vaccine Contract Manufacturing Global Market Forecast to Record Compound Annual Growth of 9% Between 2021-2026 – ResearchAndMarkets.com DUBLIN–(BUSINESS WIRE)–The “Vaccine Contract Manufacturing (..)

article thumbnail

WuXi debuts first vaccine CDMO site in China, where it plans to employ more than 500

Fierce Pharma

WuXi Vaccines launched its first standalone vaccine contract manufacturing facility in Suzhou. Amid a global expansion spree at WuXi Biologics, the company's immunization-focused subsidiary has christened its inaugural CDMO site in China.